Glaucoma Treatment Articles & Analysis: Older
36 news found
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease. ...
To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of glaucoma. ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. The poster spotlights the results ...
This alliance with iSTAR Medical is an important step as we continue to be an innovator in glaucoma by maximizing the value of interventional approaches throughout the treatment paradigm. Today’s announcement is validation of the transformational role of MINIject in the treatment of glaucoma, said Michel Vanbrabant, ...
Glucosamine is generally used in clinical treatment in the form of Glucosamine hydrochloride. People can take glucosamine hydrochloride by mouth to treat osteoarthritis, rheumatoid arthritis, glaucoma, jaw disease called temporomandibular joint disorder (TMD), joint pain, back pain, and weight loss.Specifically, glucosamine hydrochloride is often used together ...
The supraciliary space has previously been demonstrated to be one of the most efficacious targets for the reduction of eye pressure, and the potential of a new bleb-free MIGS approach with strong efficacy and good safety data represents a highly compelling treatment option for glaucoma patients.” Michel Vanbrabant, CEO of iSTAR Medical, commented: ...
At month 12, medications were reduced from 0.43 to 0.15 (P1, with a higher predisposition to glaucoma2, this published data provides visibility of results from MIGS, specifically the OMNI Surgical System, that corroborate the larger study findings while providing specific data for the Hispanic population, which has been limited up to this point. “Effective treatment backed ...
Dr Kaweh Mansouri, Glaucoma Specialist (Lausanne) commented: Glaucoma is a growing problem in the increasingly ageing Swiss population, with glaucoma incidence rising from 2% of people over the age of 50 to 5-8% in those over 70. ...
Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period Received FDA 510(k) Clearance of the TearCare® System ...
The funds raised in this Series A round are targeted primarily to support the upcoming Phase 2b clinical study along with the end of Phase 2 meeting with the FDA for its lead glaucoma asset. The funds will also be used to advance other products to clinical trials, most notably the dry eye asset. Further, the Company is excited to announce the presentation of a poster ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has commenced a Phase 2 clinical program for its third-generationiLink™ therapy designed to treat keratoconus. ...
Melbourne, Australia – March 4, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the ...
Melbourne, Australia – February 17, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa study of its PA5108 Ocular Implant for the ...
I am excited to be part of this trial and based on my positive experience thus far, I am optimistic for MINIject to be a valuable addition to our glaucoma treatment armamentarium.” Michel Vanbrabant, CEO of iSTAR Medical, commented: “Following last year’s success with the approval of MINIject in Europe, we are excited to be progressing ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia. ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. The ...
It contains information on how MediPrint Ophthalmics is initially developing a highly innovative solution for a significant unmet need in glaucoma. Also, the Company’s pipeline of products, including those for dry eye and allergy, which are all based on its proprietary MediPrint™ process and contact lenses, is highlighted. Dan Myers, the company’s CEO, was ...